No Data
No Data
ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024
ImmuCell Reports $7.3M In Product Sales For Quarter Ended March 31, 2024
ImmuCell | 10-Q: Quarterly report
Immucell 1Q Loss $438,000 >ICCC
Immucell 1Q Loss $438,000 >ICCC
Press Release: ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company")
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024.
ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9
ImmuCell Anticipates No Change To Preliminary Sales Results For Q1 Ended March 31, 2024 That Were Disclosed On April 9
No Data